ArticleOpen life sciences2026
Flaxseed oil and probiotics protect against induced nonalcoholic fatty liver disease (NAFLD) in male rats.
Article in Open life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the effect of probiotics and flaxseed oil on nonalcoholic fatty liver disease (NAFLD). 50 male albino rats were divided into five groups (10/each), the 1st negative control group fed on the basal diet (G1) and four other groups subjected to induced NAFLD and then classified into four groups; the 2nd positive control group induced-Non Alcoholic fatty liver disease (G2), the 3rd group was treated with flaxseed oil (G3), the 4th group was treated with live probiotics (G4) and the 5th group was treated with mixed of flaxseed oil and live probiotics (G5). The study was conducted for 8 weeks. GC analysis indicated that the main constituent of flaxseed oil is the omega-3 fatty acid α-linolenic acid methyl ester (44.89 %). The positive control group showed severely altered lipid profile, liver enzymes, transforming growth factor-β (TGF-β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and liver histology, whereas treating the NAFLD with flaxseed oil or probiotic strains or their mix significantly improved lipid profile, liver enzyme, transforming growth factor-β (TGF-β), inflammatory markers (tumor necrosis factor-α (TNF-α) and interleukin-6 "IL-6"), and significantly decreased oxidative stress levels than the positive control group. Flaxseed oil and probiotics, separately and in combination, confer hepatoprotective effects against induced NAFLD in rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.